Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 2Uterine Cervical Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine nonavalent 7Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 7human papillomavirus vaccine, L1 type 16, 18 6Papillomavirus Vaccines 4Vaccines 2Engerix-B 2adacel 1Vaccines, Synthetic 1Tetanus Toxoid 1Methods 1Hepatitis A Vaccines 1Educational Status 1Early Intervention, Educational 1Diphtheria-Tetanus-acellular Pertussis Vaccines 1Diphtheria Toxoid 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Papillomavirus Infections × Engerix-B × Clear all
NCT00534638 2019-11-15

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

GlaxoSmithKline

Phase 4 Completed
34,412 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01082861 2010-03-19

TANGO

National Institute for Public Health and the Environment (RIVM)

Phase 4 Terminated

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡